Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions. It operates through the following segments: Alkindi, Chronocort, and Central and Early-stage. The Alkindi segment refers to the development and supply of Alkindi product. The Chronocort segment focuses on the development of Chronocort product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency. The Central and Early-stage segment is involved in the development of the group's early-stage pipeline products. The company was founded by Richard John Martin Ross in 2004 and is headquartered in Cardiff, the United Kingdom.